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Retrograde type A aortic dissection (RTAD) during or after
thoracic endovascular aortic repair (TEVAR) is a potentially lethal
complication and has been increasingly associated with endovascu-
lar repair of aortic dissection. The incidence of RTAD, in which the
entry tear in the descending aorta propagates up to the aortic arch
or ascending aorta, varies from 10% to 27%.1 Resection of the entry
tear with replacement of the ascending aorta and aortic arch is
associated with significant morbidity and mortality, with reported
mortality rates as high as 27% according to the International
Registry for Aortic Dissection (IRAD).2 Possible etiologies for
RTAD after thoracic endografting can be classified as procedure-
related, device-related, and natural progression of disease.
This study by Fu et al comprised 650 patients who underwent
TEVAR for a mixture of acute and chronic type B aortic dissection.
Of these, 23 patients experienced “stent graft-induced new-entry”
(SINE) aortic tears after TEVAR. The authors claim that these
post-TEVAR dissections are a result of aortic wall injury by the
thoracic stent graft (ie, device-related), and report a sobering
mortality rate of 26%.
Although it is well acknowledged that RTAD is a potential
complication after TEVAR, particularly for the treatment of aortic
dissection, the challenging task, which the authors have under-
taken, is identifying the etiology of the RTAD so that its occur-
rence can be minimized. It can be extremely difficult to distinguish
between a device-related, procedure-related, and disease-related
cause of RTAD. How does one accurately determine that the
RTAD is not a result of inadequate stent graft coverage of the entry
or exit tears in the aorta, or from wire manipulation and balloon
dilation rather than from the stent graft itself?
This article defines criteria used to determine a SINE and
suggests possible mechanisms by which they occur, including the
inherent characteristic of a semirigid stent graft to “spring back”
when passively bent, such as when placed in the aortic arch,
therefore generating increased stress at the proximal end of the
stent graft that is then transmitted to the greater curvature of the
arch. In addition, the authors report several cases of devices with
bare proximal metal stents or barbs that were identified on surgical
exploration to have caused intimal tears in a fragile thoracic aorta.
It is intuitive that patients with connective tissue disorders,
such as Marfan syndrome, would be predisposed to SINE, and this
is also borne out in this study. I concur with the authors’ recom-
mendation that TEVAR should be avoided in patients withMarfan
syndrome who present with aortic dissection.
Interestingly, the degree of stent graft over-sizing, which
results in a higher radial force against the aortic wall, was not a
factor in the development of SINE. However, the article does notmention the incidence of balloon dilation after stent graft deploy-
ment to assist with graft-to-aortic wall apposition. Balloon dilation
of the endograft at the proximal and distal attachment sites in the
setting of aortic dissection is widely discouraged because it can lead
to further damage of an already fragile aortic wall. However, there
are instances when these semirigid endografts are not able to adapt
perfectly to the curve in an angulated aortic arch, and repeated
balloon dilation is required to conform the endograft to the curved
geometry of the arch to form a tight seal. This can result in intimal
tears, which may progress to frank aortic dissection. It would be
interesting to know how many patients in this study underwent
proximal or distal balloon dilation and whether this had an effect
on the incidence of SINE, because the act of balloon dilation rather
than the device itself could have been the cause of the RTAD.
This article identifies potential risk factors for SINE and sug-
gests strategies to reduce their incidence. I think it is important to
emphasize that TEVAR for the treatment of aortic dissection and
TEVAR for the treatment of aneurysmal disease are as dissimilar as
the disease processes themselves. Better patient selection, precise
stent graft deployment, careful wire and sheathmanipulation in the
aortic arch, coverage of a large part of straight portion of the
descending aorta or horizontal portion of the aortic arch as op-
posed to the angled or curved part of the aorta (thereby reducing
“spring-back” force), and avoidance of aggressive balloon dilation
of stent grafts in the treatment of type B aortic dissection can
reduce the incidence of RTAD. The inflexibility of current stent
grafts combined with the pulsatile forces of the aorta can cause
many adverse effects on an acutely dissected intima.
Development of stent grafts specifically for the treatment of
thoracic aortic dissection with flexible bodies that are able to more
easily conform to aortic arch angulation and with smoother edges,
as well as avoidance of proximal bare metal stents or barbs that
could potentially create new intimal tears, could further help
decrease this fatal complication of SINE in the endovascular treat-
ment of type B dissection.
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